Digest Network Come funziona
Network
/
Società
In
Non verificato

Innoviva, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniSaluteWeb e Social Network

25 comunicati stampa

Guarda tutti i comunicati
02/09/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Innoviva to Participate in Upcoming Investor Conferences
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
05/08/2026
Mercato azionario
Biotecnologia
Sanità
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Farmaceutica
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Eventi
Innoviva to Participate in Upcoming Investor Conferences
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Mercato azionario
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Finanza
Mercato azionario
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
19/02/2026
Web e Social Network
Eventi
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Scienza
Farmaceutica
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
12/12/2025
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Farmaceutica
Salute
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Eventi
Web e Social Network
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Web e Social Network
Telefonia e Varie
Mercato azionario
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Fonte
Innoviva, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0